|
||||||
Executive Summary Summary DiaSorin S.p.A. (DiaSorin) is a medical diagnostics company that develops, manufactures and markets in vitro diagnostics reagent kits and systems. The company develops reagent kits based on Radioimmunometry (RIA), Enzyme Linked Immunosorbent Assays (ELISA) and Chemiluminescence (CLIA) techniques, to enable automatic diagnostic investigation. The company's products find application in the diagnosis of infectious diseases, bone and mineral disorders, endocrinology, hypertension, oncology, gastrointestinal infections, autoimmune disorders, and neurological and cardiac diseases. DiaSorin markets its products through direct sales force and distributors. It has operations in North America, South America, South Africa, EMEA and Asia. DiaSorin is headquartered at Saluggia, Piemonte, Italy. This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Scope: - The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments - The report analyzes all pipeline products in development for the company DiaSorin S.p.A - The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status) - The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date - The report provides detailed description of products in development, technical specification and functions - The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date. Reasons to Buy: - Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape - Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio - To formulate effective Research & Development strategies - Develop market-entry and market expansion strategies - Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc - Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio Note: Some sections may be missing if data is unavailable for the company Read More Contact Us:
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 8 DiaSorin S.p.A Company Overview 9 DiaSorin S.p.A Company Snapshot 9 DiaSorin S.p.A Pipeline Products and Ongoing Clinical Trials Overview 9 DiaSorin S.p.A-Pipeline Analysis Overview 13 Business Description 13 DiaSorin S.p.A-Key Facts 13 DiaSorin S.p.A-Major Products and Services 14 DiaSorin S.p.A Pipeline Products by Development Stage 15 DiaSorin S.p.A Ongoing Clinical Trials by Trial Status 19 DiaSorin S.p.A Pipeline Products Overview 21 BCR-ABL ABL Assay 21 BCR-ABL ABL Assay Product Overview 21 BCR-ABL P190 + ABL Assay 22 BCR-ABL P190 + ABL Assay Product Overview 22 BCR-ABL v1.5 Assay 23 BCR-ABL v1.5 Assay Product Overview 23 C-Kit 816 Assay 24 C-Kit 816 Assay Product Overview 24 C-Kit 822 Assay 25 C-Kit 822 Assay Product Overview 25 Diagnostic Assay-Atypical Pneumonia 26 Diagnostic Assay-Atypical Pneumonia Product Overview 26 Diagnostic Assay-Chronic Kidney Disease 27 Diagnostic Assay-Chronic Kidney Disease Product Overview 27 Diagnostic Assay-Enteric Infection 28 Diagnostic Assay-Enteric Infection Product Overview 28 Diagnostic Assay-Fecal Occult Blood Assay 29 Diagnostic Assay-Fecal Occult Blood Assay Product Overview 29 Diagnostic Assay-GI Inflammation 30 Diagnostic Assay-GI Inflammation Product Overview 30 Diagnostic Assay-Group B Streptococcus Infection 31 Diagnostic Assay-Group B Streptococcus Infection Product Overview 31 Diagnostic Assay-HBsAg High Throughput 32 Diagnostic Assay-HBsAg High Throughput Product Overview 32 Diagnostic Assay-HCV II 33 Diagnostic Assay-HCV II Product Overview 33 Diagnostic Assay-HSV M + cntr 34 Diagnostic Assay-HSV M + cntr Product Overview 34 Diagnostic Assay-Lactoferrin Assay 35 Diagnostic Assay-Lactoferrin Assay Product Overview 35 Diagnostic Assay-Lipase Assay 36 Diagnostic Assay-Lipase Assay Product Overview 36 Diagnostic Assay-Mycoplasma Genitalium Infection 37 Diagnostic Assay-Mycoplasma Genitalium Infection Product Overview 37 Diagnostic Assay-Streptococcus Pneumonia 38 Diagnostic Assay-Streptococcus Pneumonia Product Overview 38 Diagnostic Assay-Vaginosis 39 Diagnostic Assay-Vaginosis Product Overview 39 Diagnostic Assay-Vector Borne Diseases 40 Diagnostic Assay-Vector Borne Diseases Product Overview 40 Estradiol II Assay 41 Estradiol II Assay Product Overview 41 H.Influenza B Assay 42 H.Influenza B Assay Product Overview 42 Human Herpes Virus 6 IgG EIA Assay 43 Human Herpes Virus 6 IgG EIA Assay Product Overview 43 Human Herpes Virus 8 IgG IFA Assay 44 Human Herpes Virus 8 IgG IFA Assay Product Overview 44 Hyperphosphate-High Bone Turnover Assay 45 Hyperphosphate-High Bone Turnover Assay Product Overview 45 LAMP CBF-MYH D Assay 46 LAMP CBF-MYH D Assay Product Overview 46 LAMP CBF-MYH E Assay 47 LAMP CBF-MYH E Assay Product Overview 47 LAMP VCA IgA Assay 48 LAMP VCA IgA Assay Product Overview 48 LIAISON-Anti-HDV Assay 49 LIAISON-Anti-HDV Assay Product Overview 49 LIAISON-Chlamydia P. IgA Assay 50 LIAISON-Chlamydia P. IgA Assay Product Overview 50 LIAISON-Chlamydia P. IgG Assay 51 LIAISON-Chlamydia P. IgG Assay Product Overview 51 LIAISON-High Sclerostin Assay 52 LIAISON-High Sclerostin Assay Product Overview 52 LIAISON-Hyperphosphate Low Bone Turnover Assay 53 LIAISON-Hyperphosphate Low Bone Turnover Assay Product Overview 53 LIAISON-Tg Gen II Assay 54 LIAISON-Tg Gen II Assay Product Overview 54 LIAISON IAM-Acute Lymphoblastic Leukemia Test 55 LIAISON IAM-Acute Lymphoblastic Leukemia Test Product Overview 55 LIAISON IAM-Acute Promyelocytic Leukemia Test 56 LIAISON IAM-Acute Promyelocytic Leukemia Test Product Overview 56 LIAISON IAM-EBV Assay 57 LIAISON IAM-EBV Assay Product Overview 57 LIAISON IAM-Myeloproliferative Neoplasm Assay 58 LIAISON IAM-Myeloproliferative Neoplasm Assay Product Overview 58 LIAISON XL-Chlamydia Pneumoniae Assay 59 LIAISON XL-Chlamydia Pneumoniae Assay Product Overview 59 LIAISON XL-H. Pylori Ag Assay 60 LIAISON XL-H. Pylori Ag Assay Product Overview 60 LIAISON XL-H. Pylori Ag Assay Clinical Trial 61 LIAISON XL-Hepatitis A Assay 62 LIAISON XL-Hepatitis A Assay Product Overview 62 LIAISON XL-Hepatitis B Assay 63 LIAISON XL-Hepatitis B Assay Product Overview 63 LIAISON XL-Hepatitis C Assay 64 LIAISON XL-Hepatitis C Assay Product Overview 64 Liaison XL-HIV 65 Liaison XL-HIV Product Overview 65 LIAISON XL-Parvovirus B19 Test 66 LIAISON XL-Parvovirus B19 Test Product Overview 66 LIAISON XL-Sclerostin Assay 67 LIAISON XL-Sclerostin Assay Product Overview 67 LIAISON XL Zika Capture IgM Assay 68 LIAISON XL Zika Capture IgM Assay Product Overview 68 LIAISON XL- Procalcitonin Assay 69 LIAISON XL- Procalcitonin Assay Product Overview 69 LIAISON XS 70 LIAISON XS Product Overview 70 Neisseria meningitidis Assay 71 Neisseria meningitidis Assay Product Overview 71 Parvovirus B19 IFA Assay 72 Parvovirus B19 IFA Assay Product Overview 72 PML-RAR Alpha BCR2 Assay 73 PML-RAR Alpha BCR2 Assay Product Overview 73 PML-RAR1 + ABL Assay 74 PML-RAR1 + ABL Assay Product Overview 74 PML-RAR2 + ABL Assay 75 PML-RAR2 + ABL Assay Product Overview 75 PML-RAR3 + ABL Assay 76 PML-RAR3 + ABL Assay Product Overview 76 Progesterone II Assay 77 Progesterone II Assay Product Overview 77 Quant ABL Assay 78 Quant ABL Assay Product Overview 78 Quant BCR-ABL p210 Assay 79 Quant BCR-ABL p210 Assay Product Overview 79 Reagent ASRs-Gastro-intestinal Infections 80 Reagent ASRs-Gastro-intestinal Infections Product Overview 80 Reagent ASRs-Genetic Disorders 81 Reagent ASRs-Genetic Disorders Product Overview 81 Reagent ASRs-Immuno-Compromised Disorders 82 Reagent ASRs-Immuno-Compromised Disorders Product Overview 82 Reagent ASRs-Infectious Disease 83 Reagent ASRs-Infectious Disease Product Overview 83 Reagent ASRs-Respiratory Disease 84 Reagent ASRs-Respiratory Disease Product Overview 84 Reagent ASRs-Vector-Borne Disease 85 Reagent ASRs-Vector-Borne Disease Product Overview 85 Respiratory Virus Panel 86 Respiratory Virus Panel Product Overview 86 Simplexa Bordetella Direct 87 Simplexa Bordetella Direct Product Overview 87 Simplexa Enterovirus Direct 88 Simplexa Enterovirus Direct Product Overview 88 Simplexa MRSA Direct 89 Simplexa MRSA Direct Product Overview 89 DiaSorin S.p.A-Key Competitors 90 DiaSorin S.p.A-Key Employees 91 DiaSorin S.p.A-Key Employee Biographies 92 DiaSorin S.p.A-Locations And Subsidiaries 93 Head Office 93 Other Locations & Subsidiaries 93 Recent Developments 95 DiaSorin S.p.A, Recent Developments 95 May 08, 2018: The Diasorin Group Reports Growth in Revenues and Profitability in the First Quarter 2018 95 Apr 05, 2018: Diasorin Receives FDA Clearance For LIAISON BRAHMS PCT II GEN Assay To Detect Severe Bacterial Infections (Sepsis) 97 Mar 28, 2018: DiaSorin Earns FDA Clearance Extending Sample Claims For HSV 1 & 2 Test 97 Dec 12, 2017: Diasorin Launches A New Simplexa Bordetella Direct Molecular Test 98 Nov 09, 2017: Growth In Revenues And Net Profit In Q3 2017. Strong Free Cash Flow Generation. 2017 Guidance Confirmed 98 Sep 26, 2017: DiaSorin Molecular Introduces Two Primer Pair Reagents for Streptococcus 99 Sep 21, 2017: Diasorin Earned CE-Mark Extending Sample Claims For Diasorin Molecular’s Simplexa HSV 1 & 2 Kit 99 Aug 03, 2017: Diasorin Group Reports Strong Growth in Revenues and Profitability in Q2 2017 99 Jul 28, 2017: Diasorin Launches 3 New Primer Pairs For Use In Molecular Testing: Pneumocystis Jirovecii, Group C Streptococcus, And Group G Streptococcus 102 Jul 10, 2017: Diasorin Launches IAM CBFB-MYH11, Completing The Diagnostic Test Menu For Molecular Screening Of Acute Myeloid Leukemia By Q-LAMP 103 Appendix 104 Methodology 104 About GlobalData 106 Contact Us 106 Disclaimer 107 List of Figures DiaSorin S.p.A Pipeline Products by Equipment Type 10 DiaSorin S.p.A Pipeline Products by Development Stage 15 DiaSorin S.p.A Ongoing Clinical Trials by Trial Status 19 List of Tables DiaSorin S.p.A Pipeline Products and Ongoing Clinical Trials Overview 9 DiaSorin S.p.A Pipeline Products by Equipment Type 10 DiaSorin S.p.A Pipeline Products by Indication 11 DiaSorin S.p.A Ongoing Clinical Trials by Trial Status 11 DiaSorin S.p.A, Key Facts 13 DiaSorin S.p.A, Major Products and Services 14 DiaSorin S.p.A Number of Pipeline Products by Development Stage 15 DiaSorin S.p.A Pipeline Products Summary by Development Stage 16 DiaSorin S.p.A Ongoing Clinical Trials by Trial Status 19 DiaSorin S.p.A Ongoing Clinical Trials Summary 20 BCR-ABL ABL Assay-Product Status 21 BCR-ABL ABL Assay-Product Description 21 BCR-ABL P190 + ABL Assay-Product Status 22 BCR-ABL P190 + ABL Assay-Product Description 22 BCR-ABL v1.5 Assay-Product Status 23 BCR-ABL v1.5 Assay-Product Description 23 C-Kit 816 Assay-Product Status 24 C-Kit 816 Assay-Product Description 24 C-Kit 822 Assay-Product Status 25 C-Kit 822 Assay-Product Description 25 Diagnostic Assay-Atypical Pneumonia-Product Status 26 Diagnostic Assay-Atypical Pneumonia-Product Description 26 Diagnostic Assay-Chronic Kidney Disease-Product Status 27 Diagnostic Assay-Chronic Kidney Disease-Product Description 27 Diagnostic Assay-Enteric Infection-Product Status 28 Diagnostic Assay-Enteric Infection-Product Description 28 Diagnostic Assay-Fecal Occult Blood Assay-Product Status 29 Diagnostic Assay-Fecal Occult Blood Assay-Product Description 29 Diagnostic Assay-GI Inflammation-Product Status 30 Diagnostic Assay-GI Inflammation-Product Description 30 Diagnostic Assay-Group B Streptococcus Infection-Product Status 31 Diagnostic Assay-Group B Streptococcus Infection-Product Description 31 Diagnostic Assay-HBsAg High Throughput-Product Status 32 Diagnostic Assay-HBsAg High Throughput-Product Description 32 Diagnostic Assay-HCV II-Product Status 33 Diagnostic Assay-HCV II-Product Description 33 Diagnostic Assay-HSV M + cntr-Product Status 34 Diagnostic Assay-HSV M + cntr-Product Description 34 Diagnostic Assay-Lactoferrin Assay-Product Status 35 Diagnostic Assay-Lactoferrin Assay-Product Description 35 Diagnostic Assay-Lipase Assay-Product Status 36 Diagnostic Assay-Lipase Assay-Product Description 36 Diagnostic Assay-Mycoplasma Genitalium Infection-Product Status 37 Diagnostic Assay-Mycoplasma Genitalium Infection-Product Description 37 Diagnostic Assay-Streptococcus Pneumonia-Product Status 38 Diagnostic Assay-Streptococcus Pneumonia-Product Description 38 Diagnostic Assay-Vaginosis-Product Status 39 Diagnostic Assay-Vaginosis-Product Description 39 Diagnostic Assay-Vector Borne Diseases-Product Status 40 Diagnostic Assay-Vector Borne Diseases-Product Description 40 Estradiol II Assay-Product Status 41 Estradiol II Assay-Product Description 41 H.Influenza B Assay-Product Status 42 H.Influenza B Assay-Product Description 42 Human Herpes Virus 6 IgG EIA Assay-Product Status 43 Human Herpes Virus 6 IgG EIA Assay-Product Description 43 Human Herpes Virus 8 IgG IFA Assay-Product Status 44 Human Herpes Virus 8 IgG IFA Assay-Product Description 44 Hyperphosphate-High Bone Turnover Assay-Product Status 45 Hyperphosphate-High Bone Turnover Assay-Product Description 45 LAMP CBF-MYH D Assay-Product Status 46 LAMP CBF-MYH D Assay-Product Description 46 LAMP CBF-MYH E Assay-Product Status 47 LAMP CBF-MYH E Assay-Product Description 47 LAMP VCA IgA Assay-Product Status 48 LAMP VCA IgA Assay-Product Description 48 LIAISON-Anti-HDV Assay-Product Status 49 LIAISON-Anti-HDV Assay-Product Description 49 LIAISON-Chlamydia P. IgA Assay-Product Status 50 LIAISON-Chlamydia P. IgA Assay-Product Description 50 LIAISON-Chlamydia P. IgG Assay-Product Status 51 LIAISON-Chlamydia P. IgG Assay-Product Description 51 LIAISON-High Sclerostin Assay-Product Status 52 LIAISON-High Sclerostin Assay-Product Description 52 LIAISON-Hyperphosphate Low Bone Turnover Assay-Product Status 53 LIAISON-Hyperphosphate Low Bone Turnover Assay-Product Description 53 LIAISON-Tg Gen II Assay-Product Status 54 LIAISON-Tg Gen II Assay-Product Description 54 LIAISON IAM-Acute Lymphoblastic Leukemia Test-Product Status 55 LIAISON IAM-Acute Lymphoblastic Leukemia Test-Product Description 55 LIAISON IAM-Acute Promyelocytic Leukemia Test-Product Status 56 LIAISON IAM-Acute Promyelocytic Leukemia Test-Product Description 56 LIAISON IAM-EBV Assay-Product Status 57 LIAISON IAM-EBV Assay-Product Description 57 LIAISON IAM-Myeloproliferative Neoplasm Assay-Product Status 58 LIAISON IAM-Myeloproliferative Neoplasm Assay-Product Description 58 LIAISON XL-Chlamydia Pneumoniae Assay-Product Status 59 LIAISON XL-Chlamydia Pneumoniae Assay-Product Description 59 LIAISON XL-H. Pylori Ag Assay-Product Status 60 LIAISON XL-H. Pylori Ag Assay-Product Description 60 LIAISON XL-H. Pylori Ag Assay-Helicobacter Pylori Sample Collection Protocol Post-therapy 61 LIAISON XL-H. Pylori Ag Assay-Helicobacter Pylori Sample Collection Protocol Pre-therapy 61 LIAISON XL-Hepatitis A Assay-Product Status 62 LIAISON XL-Hepatitis A Assay-Product Description 62 LIAISON XL-Hepatitis B Assay-Product Status 63 LIAISON XL-Hepatitis B Assay-Product Description 63 LIAISON XL-Hepatitis C Assay-Product Status 64 LIAISON XL-Hepatitis C Assay-Product Description 64 Liaison XL-HIV-Product Status 65 Liaison XL-HIV-Product Description 65 LIAISON XL-Parvovirus B19 Test-Product Status 66 LIAISON XL-Parvovirus B19 Test-Product Description 66 LIAISON XL-Sclerostin Assay-Product Status 67 LIAISON XL-Sclerostin Assay-Product Description 67 LIAISON XL Zika Capture IgM Assay-Product Status 68 LIAISON XL Zika Capture IgM Assay-Product Description 68 LIAISON XL- Procalcitonin Assay-Product Status 69 LIAISON XL- Procalcitonin Assay-Product Description 69 LIAISON XS-Product Status 70 LIAISON XS-Product Description 70 Neisseria meningitidis Assay-Product Status 71 Neisseria meningitidis Assay-Product Description 71 Parvovirus B19 IFA Assay-Product Status 72 Parvovirus B19 IFA Assay-Product Description 72 PML-RAR Alpha BCR2 Assay-Product Status 73 PML-RAR Alpha BCR2 Assay-Product Description 73 PML-RAR1 + ABL Assay-Product Status 74 PML-RAR1 + ABL Assay-Product Description 74 PML-RAR2 + ABL Assay-Product Status 75 PML-RAR2 + ABL Assay-Product Description 75 PML-RAR3 + ABL Assay-Product Status 76 PML-RAR3 + ABL Assay-Product Description 76 Progesterone II Assay-Product Status 77 Progesterone II Assay-Product Description 77 Quant ABL Assay-Product Status 78 Quant ABL Assay-Product Description 78 Quant BCR-ABL p210 Assay-Product Status 79 Quant BCR-ABL p210 Assay-Product Description 79 Reagent ASRs-Gastro-intestinal Infections-Product Status 80 Reagent ASRs-Gastro-intestinal Infections-Product Description 80 Reagent ASRs-Genetic Disorders-Product Status 81 Reagent ASRs-Genetic Disorders-Product Description 81 Reagent ASRs-Immuno-Compromised Disorders-Product Status 82 Reagent ASRs-Immuno-Compromised Disorders-Product Description 82 Reagent ASRs-Infectious Disease-Product Status 83 Reagent ASRs-Infectious Disease-Product Description 83 Reagent ASRs-Respiratory Disease-Product Status 84 Reagent ASRs-Respiratory Disease-Product Description 84 Reagent ASRs-Vector-Borne Disease-Product Status 85 Reagent ASRs-Vector-Borne Disease-Product Description 85 Respiratory Virus Panel-Product Status 86 Respiratory Virus Panel-Product Description 86 Simplexa Bordetella Direct-Product Status 87 Simplexa Bordetella Direct-Product Description 87 Simplexa Enterovirus Direct-Product Status 88 Simplexa Enterovirus Direct-Product Description 88 Simplexa MRSA Direct-Product Status 89 Simplexa MRSA Direct-Product Description 89 DiaSorin SpA, Key Employees 91 DiaSorin S.p.A, Key Employee Biographies 92 DiaSorin SpA, Other Locations 93 DiaSorin SpA, Subsidiaries 93 Glossary 105 Single User License: Site License: Corporate User License: Trinity Biotech Plc Roche Diagnostics SpA Randox Laboratories Ltd EKF Diagnostics Holdings Plc Biohit Oyj DiaSorin S.p.A, Product, Pipeline, Product Pipeline, Key Pipeline, Products by Equipment Type, Equipment Type, Therapy Area, Products by Therapy Area, Development Stage, Products by Development Stage, Milestone, Products by Milestone, Major Products, Brands, No of Products, Device Class, Market, Territory, Product Name, Therapy Name, Trial Name, Trial, Indication, Summary, Event Type, Clinical Trial, MileStone, Product Status, Product Description, Description, Patent, Patent Details, Competitors, Key Employees, Subsidiaries, Locations, News, Events, Developments, medical devices, business description, company facts, trial phase, approval, estimated, technology, product patent details, phase, trial status, trial objective, trial design, trial site, business strategies, trends, pipeline and technology, sales strategies |
select a license |
||
NEWSLETTER BY CATEGORY
|
||
Testimonials
|
||
The report was very informative and gives me an interesting view on the Indian market.... "Area Sales Manager, Muhlen Sohn GmbH & Co. KG"We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help... "Group Vice President Strategy, Aliaxis"I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again... "Technical Marketing Manager, Ascendis Health Limited"I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ... "., Coldwell Banker - Riyadh "The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future... "International and Business Dev. Director, Duta Abadi Primantara" |